I am a molecular epidemiologist, studying the environmental and genetic causes of cancer, particularly endometrial and breast cancer. I am studying the molecular markers that act as signatures for the environmental and-or genetic aetiology of a given canc
Biomarkers Of Phenotype, Prognosis And Response To Therapy In Pancreatic Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$105,845.00
Summary
Pancreatic cancer (PC) is the 4th leading cause of cancer deaths in our society. This research is aimed at the discovery of novel biomarkers with the ability to forecast prognosis and response to treatments in patients with PC. Ultimately, this will lead to the “individualisation” of the treatment for each patient, so that the most appropriate therapy could be given to an individual patient. This would significantly improve the overall survival and the quality of life for patients.
Tubulovillous Adenomas In Colorectal Tumorigenesis
Funder
National Health and Medical Research Council
Funding Amount
$295,983.00
Summary
Bowel cancer is the second most common cancer affecting Australians today, and half of all patients will not survive their disease. Bowel cancer grows from small growths called polyps. In this project, we aim to investigate changes in genes found in a particularly aggressive type of bowel polyp called a tubulovillous adenoma. A better understanding of these gene changes will aid the future development of molecular tests for early detection and therapeutic options for the treatment of cancer.
The CpG Island Methylator Phenotype In Colorectal Cancer - Pathways And Precursors
Funder
National Health and Medical Research Council
Funding Amount
$517,272.00
Summary
Bowel cancer is one of the most common cancers affecting Australians. It will affect 1-23 Australians and is a leading cause of cancer-related death. If diagnosed early, bowel cancer is curable with surgery. Unfortunately, symptoms are often not present until the cancer is advanced, when the cure rate is only 55%. It has been recognised that there are different types of bowel cancer depending on different genes which can be inactivated abnormally. We propose that there are at least four differen ....Bowel cancer is one of the most common cancers affecting Australians. It will affect 1-23 Australians and is a leading cause of cancer-related death. If diagnosed early, bowel cancer is curable with surgery. Unfortunately, symptoms are often not present until the cancer is advanced, when the cure rate is only 55%. It has been recognised that there are different types of bowel cancer depending on different genes which can be inactivated abnormally. We propose that there are at least four different subgroups of bowel tumours, and that each of these may have different physical properties and responses to therapy. We aim to better characterise these subgroups to increase our understanding of how normal bowel can change into a small polyp, that may grow into a cancer. Understanding the gene changes leading to each subtype of bowel cancer will in the future allow the development gene markers for early detection as well as the possibility of individualised patient therapy. We are also studying tiny biopsies of normal bowel tissue from patients either with or without polyps, to try to understand the very earliest changes which may underly the development of a bowel polyp.Read moreRead less
Novel Molecular Markers Of Lung Cancer Risk And Survival
Funder
National Health and Medical Research Council
Funding Amount
$824,765.00
Summary
Lung cancer remains the most lethal cancer worldwide, yet little is known of the risk factors beyond that of tobacco smoking and certain occupational exposures. We have assembled a large international consortium comprising 24 cohort studies and over 10,000 to validate associations between B-vitamins and lung cancer risk particularly in never and former smokers. We propose to expand this study and use the Melbourne Collaborative Cohort Study and the rest of the consortium to identify novel biomar ....Lung cancer remains the most lethal cancer worldwide, yet little is known of the risk factors beyond that of tobacco smoking and certain occupational exposures. We have assembled a large international consortium comprising 24 cohort studies and over 10,000 to validate associations between B-vitamins and lung cancer risk particularly in never and former smokers. We propose to expand this study and use the Melbourne Collaborative Cohort Study and the rest of the consortium to identify novel biomarkers of risk and survival.Read moreRead less
Blood Biomarker Discovery For The Diagnosis Of Alzheimers Disease
Funder
National Health and Medical Research Council
Funding Amount
$292,639.00
Summary
Alzheimer's disease (AD) currently affects approximately 24 million people world wide, with >200,000 people within Australia currently affected, by 2050 an estimated 730,000+ people will be affected. The discovery of blood based biomarkers for AD will enable earlier diagnosis of AD, allowing early preventative treatments to be given. Thus, reduce the rate of disease progression and the cost of care and, gain significant improvement in the quality of life for the patients and their families.
Australian Prostate Cancer Collaboration (APCC) Bio-Resource
Funder
National Health and Medical Research Council
Funding Amount
$2,310,000.00
Summary
The Australian Prostate Cancer Collaboration (APCC), supported by the Commonwealth Bank, Prostate Cancer Foundation of Australia and Andrology Australia, has been developing an Australia-wide network of prostate tissue banks and associated clinical databases for the past 3 years. The concept of this innovative project is to establish “nodes” or branches of the tissue bank in each State where tissues are collected and to coordinate the use of this material from a central committee or “head office ....The Australian Prostate Cancer Collaboration (APCC), supported by the Commonwealth Bank, Prostate Cancer Foundation of Australia and Andrology Australia, has been developing an Australia-wide network of prostate tissue banks and associated clinical databases for the past 3 years. The concept of this innovative project is to establish “nodes” or branches of the tissue bank in each State where tissues are collected and to coordinate the use of this material from a central committee or “head office”. A website has been established (www.apccbioresource.org.au) that is the national face of this ‘virtual’ national tissue bank and 7 State-based tissue bank consortiums are participating in this venture. The goal of this ‘virtual bank’ or network is to further enhance the national research effort by facilitating greater collaboration nationally and providing better access to, and optimal utilisation of, the clinical material available to facilitate improvements in prostate cancer management. Operational support for the nodes is critical for the success of a national Bio-Resource.Read moreRead less
Molecular Epidemiology And High Resolution Surveillance Of Salmonella Enterica Serovar Typhimurium In Australia
Funder
National Health and Medical Research Council
Funding Amount
$583,180.00
Summary
Salmonella typhimurium is a leading cause of the food-borne disease – salmonellosis. It is responsible for considerable morbidity and has an enormous economic cost. Molecular typing is the key to rapidly identify and control outbreaks. This project will employ next generation sequencing technology to develop a new molecular typing scheme. A surveillance system that integrates molecular typing data and epidemiological data will be developed for outbreak investigation and disease prevention.
Circulating Tumour DNA As A Marker Of Complete Pathological Response And Long Term Outcome For Locally Advanced Rectal Cancer Treated With Pre-operative Chemoradiotherapy
Funder
National Health and Medical Research Council
Funding Amount
$613,183.00
Summary
Rectal cancers are often treated by chemoradiotherapy (CRT) followed by surgery which may result in long-term stoma. A significant proportion of these patients can achieve complete remission to CRT alone. This project will assess the accuracy of a promising blood marker (circulating tumour DNA) for predicting response to treatment in patients with rectal cancer undergoing CRT. If confirmed to be a reliable marker, this test could be used to select patients who may be able to avoid or delay surge ....Rectal cancers are often treated by chemoradiotherapy (CRT) followed by surgery which may result in long-term stoma. A significant proportion of these patients can achieve complete remission to CRT alone. This project will assess the accuracy of a promising blood marker (circulating tumour DNA) for predicting response to treatment in patients with rectal cancer undergoing CRT. If confirmed to be a reliable marker, this test could be used to select patients who may be able to avoid or delay surgery.Read moreRead less